Pfizer announced that its experimental drug atirmociclib, when used in combination with the hormone therapy fulvestrant, reduced the risk of disease progression or death by 40% in patients with breast cancer in a mid-stage clinical trial.
The study evaluated the combination in patients with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer whose disease had spread and who had previously received treatment. These patients had experienced disease progression following prior use of widely used CDK4/6 inhibitors, a group that is harder to treat. According to the company, more than 90% of participants began treatment with atirmociclib within three months of discontinuing their prior therapy.
The trial compared the atirmociclib and fulvestrant combination against two alternative regimens: fulvestrant alone, or a combination of everolimus and exemestane, a commonly used targeted therapy approach for postmenopausal patients with this type of breast cancer.
Atirmociclib met the primary goal of the study by improving progression-free survival. The results were consistent across multiple patient subgroups, including performance status, menopausal status, presence of visceral disease, duration of prior treatment, and the specific CDK4/6 inhibitor previously received.
“The drug that could one day replace Ibrance as Pfizer’s leading breast cancer offering improved progression-free survival, with a 40% reduction in the risk of disease progression or death during a mid-stage trial,” Pfizer said.
The company also reported that the treatment demonstrated a manageable safety profile. According to Pfizer, 6.4% of patients discontinued therapy due to treatment-emergent adverse events, a rate consistent with previous studies.
Overall survival data, which was a secondary endpoint of the study, remains early and is not yet ready for conclusions at this stage, the company stated.
Atirmociclib is an oral drug designed to target CDK4, a cell-cycle protein that drives tumor growth. Pfizer is positioning the drug as a potential successor to its existing breast cancer therapy, Ibrance, which is expected to face patent expiration in the coming years.
In 2025, Ibrance generated $1.04 billion in sales, leading Pfizer’s oncology portfolio. However, sales have begun to decline, with a reported 5% decrease compared to 2024. The company has indicated that atirmociclib could play a role in maintaining its presence in the breast cancer treatment market as Ibrance approaches a patent cliff anticipated in 2027.
Pfizer said the results support plans to evaluate atirmociclib in earlier treatment settings, including first-line and early-stage breast cancer. A large late-stage study in newly diagnosed metastatic breast cancer patients is already underway.
The company is also advancing atirmociclib for use in earlier lines of therapy, where longer-lasting disease control could benefit a larger portion of patients. According to estimates cited by BMO Capital Markets, first-line patients with HR-positive, HER2-negative disease represent approximately 65% to 70% of the overall breast cancer population.
How Atirmociclib Works
Atirmociclib targets specific pathways involved in cancer cell growth and proliferation. By combining Atirmociclib with other therapies, Pfizer aims to enhance efficacy and provide patients with more robust treatment options.
Safety and Tolerability
The combination therapy was generally well tolerated, with side effects consistent with previous studies. Pfizer confirmed that Atirmociclib’s safety profile remains favorable, supporting its continued development.
Pfizer has released encouraging results from a mid-stage breast cancer study, showing that their combination therapy achieved a 40% reduction in the risk of disease progression. This finding represents a significant advancement for patients with advanced breast cancer.
Clinical Efficacy
Patients receiving the combination therapy experienced slower disease progression compared to standard treatment options. The study results highlight the potential of innovative treatment combinations to improve patient outcomes in mid-stage breast cancer.
Mechanism of Action
The therapy targets specific pathways that drive cancer cell growth and proliferation. By combining multiple therapeutic approaches, the treatment aims to enhance efficacy and provide more robust results for patients.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
